They specialize in multi-target biologic technologies that modulate inflammation, promote cell recovery, and facilitate tissue healing. With a strong clinical pipeline, they address various medical needs in cardiovascular, ocular, wound management, and osteoarthritic indications. Eliksa Therapeutics offers clients human doses without any reported side effects, thanks to their proprietary technology and cGMP production facility. Their lead candidate, ELK-003, is a safe and well-tolerated multi-target biological that has undergone over 18,000 human doses. As a venture-backed company, Eliksa Therapeutics aims to meet unmet medical needs in ocular and cardiovascular indications.